Improved prediction of myelotoxicity using a patient-specific imaging dose estimate for non-marrow-targeting 90Y-antibody therapy

Journal of Nuclear Medicine

Volumn 43, Issue 9, 2002, Pages 1245-1253

  Shen, Sui ^a   Meredith, Ruby F ^a   Duan, Jun ^a   Macey, Daniel J ^a   Khazaeli, M B ^a   Robert, Francisco ^a   LoBuglio, Albert F ^a  

^a The University of Alabama at Birmingham   (United States)

Author keywords

Bone marrow; Cancer; Dosimetry; Radioimmunotherapy; Toxicity

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; ETOPOSIDE; INDIUM 111; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CC49; PACLITAXEL; RADIOPHARMACEUTICAL AGENT; YTTRIUM 90;

ARTICLE; BONE MARROW; BONE MARROW TOXICITY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; COLLIMATOR; DOSIMETRY; DRUG INDUCED DISEASE; HUMAN; IMAGING SYSTEM; LUMBAR SPINE; LUNG CANCER; LUNG NON SMALL CELL CANCER; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RADIATION DOSE; RADIOIMMUNOTHERAPY; THROMBOCYTOPENIA; TRABECULAR BONE; VERTEBRA;

ADULT; AGED; ANIMALS; ANTIGENS, NEOPLASM; BONE MARROW; CARCINOMA, NON-SMALL-CELL LUNG; GLYCOPROTEINS; HUMANS; INDIUM RADIOISOTOPES; LUMBAR VERTEBRAE; LUNG NEOPLASMS; MICE; MIDDLE AGED; RADIATION DOSAGE; RADIOIMMUNOTHERAPY; RADIOMETRY; THROMBOCYTOPENIA; YTTRIUM RADIOISOTOPES;

EID: 0036733628     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Bone marrow dosimetry and toxicity for radioimmunotherapy
2. Differential reactivity of monoclonal antibodies with human colon adenocarcinomas and adenomas
3. Intraperitoneal radioimmuno-therapy of ovarian cancer with lutetium-177-CC49
4. Bone marrow dosimetry for radioimmunotherapy: Theoretical considerations
5. Treatment of metastatic prostate carcinoma with radiolabeled antibody CC49
6. A direct approach for determining marrow radiation from MoAb therapy
7. Estimation of radiation absorbed doses to the red marrow in radioimmunotherapy
8. Prediction of myelotoxicity using radiation doses to marrow from body, blood and marrow sources
9. Quantitative pharmacokinetics of radiolabeled monoclonal antibodies for imaging and therapy in patients
10. Quantitative bremsstrahlung imaging of yttrium-90 using a Wiener filter
11. MIRDOSE: Personal computer software for internal dose assessment in nuclear medicine
12. Electron absorbed fractions and dose conversion factors for marrow and bone by skeletal regions
13. Patient-specific whole-body dosimetry: Principles and a simplified method for clinical implementation
14. 131I-Lym-1 as a model
15. Marrow toxicity and radiation absorbed dose estimates from rhenium-186-labeled monoclonal antibody
16. 131I-CC49 radioimmunotherapy in three phase II clinical trials
17. 131I-labeled anticarcinoembryonic antigen monoclonal antibodies
18. 90Y-zevalin (yttrium-90 ibritumomab tiuxetan. IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin's lymphoma
19. 90Y-DOTA-biotin with pretargeted NR-LU-10/streptavidin
20. Practical determination of patient-specific marrow dose using radioactivity concentration in blood and body
21. Red marrow dosimetry for radiolabeled antibodies that bind to marrow, bone, or blood components
22. Sacral scintigraphy for bone marrow dosimetry in radioimmunotherapy
23. Quantification of iodine-131 in tumors using a threshold based on image contrast
24. Reproducibility of operator processing for radiation dosimetry
25. 111In radiolabels
26. Plasma FLT3-L levels predict bone marrow recovery from myelosuppressive therapy